Information letter to healthcare professionals regarding the medicinal product SANGERA (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

29.04.2026 356 views

Information letter to healthcare professionals on the medicinal product SANGERA (tranexamic acid). Intravenous forms of tranexamic acid – serious adverse reactions, including fatal ones, due to inadvertent intrathecal administrationPDF · 330 KB

Завантажити

Information letter to healthcare professionals regarding the medicinal product SANGERA (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product SANGERA (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration